Golden Age Health is co-founded and chaired by Michel Vounatsos, former Biogen CEO and Merck President

Golden Age Health 由前百健（Biogen）首席执行官兼默克（Merck）总裁米歇尔·沃纳佐斯（Michel Vounatsos）联合创立并担任董事长。

NEW YORK and ATHENS, Greece and SINGAPORE

纽约、希腊雅典和新加坡

,

，

Oct. 26, 2026

2026年10月26日

/PRNewswire/ -- Kos Biotechnology Partners ('Kos'), a global life sciences investment firm bridging the U.S. and European biopharma ecosystems, today announced a strategic investment in Golden Age Health (GAH) through its inaugural fund, Kos BioVentures. As part of this partnership, Alex Tzoukas, Managing Partner and Co-Founder of Kos Biotechnology Partners, will join the Golden Age Health Board of Directors..

/美通社/ -- 全球生命科学投资公司 Kos Biotechnology Partners（简称“Kos”）致力于连接美国与欧洲的生物制药生态系统，今日宣布通过其首支基金 Kos BioVentures 对 Golden Age Health（简称“GAH”）进行战略投资。作为此次合作的一部分，Kos Biotechnology Partners 的管理合伙人兼联合创始人 Alex Tzoukas 将加入 Golden Age Health 董事会。

Golden Age Health is an innovative specialty pharmaceutical platform dedicated to bringing approved and near-approved rare and specialty disease medicines to underserved patient populations across Greater China, Southeast Asia, and the Gulf regions. Kos Biotechnology Partners, backed by institutional investors including the Hellenic Development Bank of Investments (HDBI), leverages its distinct US and European footprint to connect international therapeutic breakthroughs with major global commercial pathways..

Golden Age Health 是一个创新的专科制药平台，致力于将已获批及接近获批的罕见病和专科疾病药物带给大中华区、东南亚及海湾地区医疗资源不足的患者群体。Kos Biotechnology Partners 在包括希腊投资发展银行（HDBI）在内的机构投资者支持下，凭借其独特的美国和欧洲布局，将国际治疗突破与全球主要商业化渠道相连接。

The investment will be used to fuel the expansion of Golden Age Health's commercial presence and portfolio in Greater China and Asia-Pacific, and accelerate the cross-border flow of biotech innovation between Western markets and Asia.

该投资将用于推动Golden Age Health在大中华区及亚太地区的商业布局和产品组合扩张，并加速生物科技创新在西方市场与亚洲之间的跨境流动。

'Golden Age Health has built an exceptional operational framework capable of managing complex regulatory and commercial landscapes that many Western biotech companies simply cannot navigate alone,' said

“Golden Age Health 构建了一个卓越的运营框架，能够应对复杂的监管和商业环境，而许多西方生物科技公司仅凭自身力量难以驾驭。”

Alex Tzoukas, Co-Founder and Managing Partner at Kos Biotechnology Partners and newly appointed Board Member of Golden Age Health

Alex Tzoukas，Kos Biotechnology Partners 的联合创始人兼管理合伙人，以及新近任命的 Golden Age Health 董事会成员

. 'I look forward to working closely with Michel, Yossi, Reda, and the Board to help scale their commercial footprint and infrastructure, expand their innovative portfolio, and create a two-way bridge that also brings high-potential Asian biotech innovation into Western clinical pipelines.'

“我期待与米歇尔、约西、雷达以及董事会密切合作，帮助扩大其商业布局和基础设施，拓展其创新产品组合，并搭建一座双向桥梁，将具有高潜力的亚洲生物科技创新引入西方临床研发管线。”

'We are thrilled to welcome the experienced team at Kos Biotechnology Partners as a strategic investor and Alex Tzoukas to our Board of Directors at this pivotal stage of our growth,' added

“在我们发展的这一关键阶段，我们很高兴地欢迎经验丰富的 Kos Biotechnology Partners 团队作为战略投资者加入，并欢迎 Alex Tzoukas 加入我们的董事会。”他补充道。

Michel Vounatsos, Co-Founder and Executive Chairman of Golden Age Health

米歇尔·武纳佐斯，Golden Age Health 联合创始人兼执行董事长

. 'Our mission has always been to put patients first by establishing robust ecosystems that translate clinical innovation into tangible patient access, and Alex and Simos share this deep vision. Their transatlantic reach and biopharma and investment expertise will be instrumental as we scale our portfolio of approved rare disease medicines and solidify our position as the partner of choice for global biopharma in Greater China and Asia-Pacific.'.

“我们的使命始终是以患者为先，通过构建强大的生态系统，将临床创新转化为患者切实可及的治疗方案。Alex 和 Simos 也秉持这一深远愿景。他们的跨大西洋业务网络以及在生物制药和投资领域的专业经验，将在我们扩大已获批罕见病药物组合、巩固我们作为大中华区及亚太地区全球生物制药首选合作伙伴的地位过程中发挥关键作用。”

'Kos brings institutional capital and a vast network at the point where our China business is scaling and our partnership pipeline is maturing,' said

“在我们中国业务规模化发展、合作渠道日益成熟之际，Kos 带来了机构资本和庞大的网络资源，”

Yossi Ben Amram, Co-Founder and Chief Strategy & Operations Officer of Golden Age Health

约西·本·阿姆拉姆，Golden Age Health 联合创始人兼首席战略与运营官

. 'Alex's experience on the Board will strengthen our governance as we prepare the company for its next stage of growth.'

“亚历克斯在董事会的经验将加强我们的治理，为公司下一阶段的增长做好准备。”

'We are very excited to partner with Michel and his co-founders at Golden Age Health and back a world-class leadership team that is solving one of the most critical challenges in modern medicine: regional market access for rare diseases,' said

“我们非常兴奋能与Michel及其在Golden Age Health的联合创始人合作，并支持这支世界级的领导团队，他们正在解决现代医学中最关键的挑战之一：罕见病的区域市场准入。”

Dr. Simos Simeonidis, Co-Founder and Managing Partner at Kos Biotechnology Partners

西蒙斯·西梅奥尼迪斯博士，Kos 生物技术合伙公司的联合创始人兼管理合伙人

. 'By combining Kos' biopharma network and life sciences investment expertise with Golden Age Health's unique operational capabilities, we are building a seamless gateway that ensures breakthrough therapies reach the patients who need them most, regardless of geography.'

“通过将 Kos 的生物制药网络及生命科学投资专业能力与 Golden Age Health 独特的运营能力相结合，我们正在构建一个无缝衔接的通道，确保突破性疗法能够惠及最需要的患者，无论其身处何地。”

About Kos Biotechnology Partners

关于 Kos 生物技术合作伙伴

Kos Biotechnology Partners is a global life sciences investment firm based in New York and Athens, Greece. Founded by Dr. Simos Simeonidis and Alex Tzoukas, Kos manages $125 million in assets and invests across all stages of development in therapeutic breakthroughs, biodefense, and tech-enabled pharma services.

Kos Biotechnology Partners 是一家全球生命科学投资公司，总部位于纽约和希腊雅典。由 Simos Simeonidis 博士和 Alex Tzoukas 创立，Kos 管理着 1.25 亿美元的资产，投资于治疗突破、生物防御以及技术赋能的制药服务的所有发展阶段。

For more information, visit kosbp.com..

更多信息，请访问 kosbp.com。

About Golden Age Health

关于黄金时代健康

Golden Age Health (GAH) is a Singapore-headquartered commercial platform for rare and specialty disease medicines in Greater China and Asia-Pacific. GAH partners with Western and Asian biopharma companies to bring approved and near-approved therapies to patients, acting as their commercial partner through flexible models that range from commercial services, distribution and promotion to profit-share and in-licensing.

Golden Age Health（GAH）是一家总部位于新加坡的商业平台，专注于为大中华区及亚太地区的罕见病和 specialty 疾病药物提供商业化服务。GAH 与西方及亚洲的生物制药公司合作，将已获批或接近获批的疗法带给患者，作为其商业合作伙伴，通过灵活的合作模式，涵盖商业服务、分销与推广，到利润分享和许可引进等多种形式。

GAH offers an end-to-end model covering regulatory strategy, market access, commercialization and real-world evidence generation. The company was co-founded in 2023 by Michel Vounatsos, former CEO of Biogen, Yossi Ben Amram, former President EURAM at MSD, and Reda Rebib, former healthcare investor at EQT.

GAH 提供涵盖监管战略、市场准入、商业化及真实世界证据生成的端到端模型。该公司由百健前首席执行官米歇尔·沃纳措斯、默沙东前欧洲美洲区总裁约西·本·阿姆拉姆，以及 EQT 前医疗健康投资者雷达·雷比卜于 2023 年联合创立。

Learn more at .

了解更多，请访问。

www.gahbioventures.com

www.gahbioventures.com

.

。

Media Contact:

媒体联系人：

Kos Biotechnology Partners

科斯生物技术合作伙伴

[email protected]

[email protected]

Golden Age Health

黄金时代健康

[email protected]

[email protected]

SOURCE Kos Biotechnology Partners

来源：Kos 生物技术合作伙伴